US · SYK
Stryker Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Portage, MI 49002
- Website
- stryker.com
Price · as of 2025-12-31
$294.73
Market cap 148.28B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $293.34 | -0.47% |
| Intrinsic Value(DCF) | $172.32 | -41.53% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $160.04 | -45.7% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $44.43 | $66.40 | $27.32 | $21.09 | $72.90 |
| 2012 | $56.12 | $74.20 | $43.54 | $21.24 | $41.43 |
| 2013 | $70.84 | $77.55 | $13.49 | $11.14 | $32.28 |
| 2014 | $80.40 | $74.12 | $17.91 | $0.14 | $20.43 |
| 2015 | $93.87 | $86.06 | $14.43 | $9.97 | $41.30 |
| 2016 | $117.82 | $112.51 | $26.55 | $7.78 | $93.91 |
| 2017 | $152.68 | $118.19 | $24.12 | $0.00 | $47.74 |
| 2018 | $173.83 | $148.10 | $46.30 | $27.77 | $160.80 |
| 2019 | $174.37 | $151.25 | $28.38 | $6.64 | $95.36 |
| 2020 | $228.65 | $167.74 | $3.40 | $0.00 | $19.96 |
| 2021 | $237.67 | $193.77 | $9.18 | $0.00 | $140.14 |
| 2022 | $257.10 | $190.08 | $0.00 | $0.00 | $97.21 |
| 2023 | $351.35 | $245.28 | $70.52 | $5.51 | $157.11 |
| 2024 | $375.82 | $269.37 | $30.72 | $3.83 | $140.51 |
| 2025 | $387.02 | $293.34 | $17.87 | $0.00 | $160.04 |
AI valuation
Our deep-learning model estimates Stryker Corporation's (SYK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $293.34
- Current price
- $294.73
- AI upside
- -0.47%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$172.32
-41.53% upside
Graham-Dodd
—
— upside
Graham Formula
$160.04
-45.7% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SYK | Stryker Corporation | $294.73 | 148.28B | -0% | -42% | — | -46% | 45.57 | 6.60 | 5.89 | 25.13 | 552.53 | -57.96 | 63.96% | 19.47% | 12.92% | 15.08% | 11.08% | 7.15% | 0.66 | 8.05 | 1.89 | 1.04 | 1.72 | 825.00% | 1116.00% | 2283.00% | 2.90% | 0.65 | 13.50% | 0.87% | 39.60% | 0.87% | 32.46 | 37.05 | 6.32 | 4.53 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| BSX | Boston Scientific Corpora… | $76.85 | 114.04B | -12% | -35% | -82% | -31% | 39.02 | 4.66 | 5.62 | 33.01 | 70.68 | -105.55 | 69.01% | 19.78% | 14.38% | 12.57% | 10.11% | 6.96% | 0.51 | 11.38 | 1.62 | 0.91 | 2.78 | 5520.00% | 1987.00% | 3830.00% | 3.24% | 0.83 | 10.90% | 0.00% | 0.00% | 0.32% | 31.03 | 33.68 | 6.14 | 4.56 |
| DHR | Danaher Corporation | $210.64 | 148.95B | -10% | -58% | -90% | -73% | 40.32 | 2.77 | 5.93 | 22.97 | — | -17.28 | 60.93% | 20.91% | 14.71% | 7.08% | 6.70% | 4.49% | 0.35 | 19.38 | 1.87 | 1.25 | 1.99 | -473.00% | 290.00% | -68.00% | 3.61% | 0.94 | 8.03% | 0.60% | 24.30% | 3.59% | 31.05 | 30.32 | 6.49 | 4.20 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| HCA | HCA Healthcare, Inc. | $529.70 | 118.45B | -26% | -56% | -86% | -18% | 18.12 | -20.40 | 1.63 | 11.03 | 62.49 | -7.53 | 41.50% | 15.83% | 8.97% | -159.14% | 22.59% | 11.28% | -8.33 | 5.32 | 0.83 | 0.73 | 3.15 | 2900.00% | 708.00% | 3641.00% | 6.26% | 0.77 | 18.35% | 0.55% | 10.00% | 8.74% | 14.38 | 22.37 | 2.28 | 2.87 |
| MCK | McKesson Corporation | $987.37 | 121.87B | -46% | +187% | — | -38% | 26.01 | -43.65 | 0.25 | 17.57 | 174.88 | -6.68 | 3.48% | 1.22% | 0.92% | -172.11% | 1514.70% | 4.88% | -3.56 | 17.08 | 0.90 | 0.51 | 0.32 | 1487.00% | 1622.00% | 4409.00% | 5.77% | 0.10 | 2267.25% | 0.38% | 9.90% | 5.08% | 21.10 | 17.65 | 0.26 | 5.91 |
| MDT | Medtronic plc | $97.66 | 125.38B | — | -51% | — | -81% | 41.30 | 2.92 | 4.98 | 22.00 | — | -18.12 | 65.19% | 14.89% | 11.97% | — | — | — | 0.51 | 4.85 | 2.65 | 1.91 | 3.03 | — | — | — | 3.26% | 0.73 | — | 2.08% | 86.00% | 2.52% | 36.91 | 33.88 | 5.50 | 3.26 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| VRTX | Vertex Pharmaceuticals In… | $496.83 | 126.19B | -25% | -45% | -71% | -46% | 31.44 | 6.66 | 10.29 | 24.47 | — | 7.25 | 85.03% | 39.43% | 32.74% | 22.54% | 28.97% | 16.24% | 0.21 | 357.95 | 2.90 | 2.24 | -0.24 | -83654.00% | 957.00% | -50413.00% | 2.57% | 0.94 | 22.83% | 0.00% | 0.00% | 1.62% | 25.53 | 38.06 | 10.07 | 12.10 |
About Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
- CEO
- Kevin A. Lobo
- Employees
- 53K
- Beta
- 0.87
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($172.32 ÷ $294.73) − 1 = -41.53% (DCF, example).